Characteristics of the exeter IPF cohort (SD=standard deviation)
| IPF patients | n=90 |
|---|---|
| Age (years) (SD) | 74 (9) |
| Gender, male | 76 (84%) |
| Current Treatment | n= 90 |
| Nintedanib | 55 (61%) |
| Pirfenidone | 35 (39%) |
| Comorbidities | |
| Ischaemic heart disease | 23 (26%) |
| Hypertension | 18 (20%) |
| Gastroesophageal Reflux Disease | 17 (19%) |
| Type 2 Diabetes Mellitus | 14 (16%) |
| Osteoarthritis | 9 (10%) |
| Hypothyroidism | 7 (8%) |
| Hypercholesterolaemia | 6 (7%) |
| Asthma | 5 (6%) |
| Inflammatory bowel disease | 3 (3%) |
| Other connective tissue disease | 3 (3%) |
| Gout | 3 (3%) |
| Chronic Kidney disease | 2 (2%) |
| Obstructive sleep apnoea | 1 (1%) |
| WHO BMI Classification | n= 46 |
| Underweight (<18.5) | 0 |
| Normal (18.5–24.99) | 10 (22%) |
| Pre-obese (25–29.99) | 17 (37%) |
| Obese Class 1 or 2 (30–39.99) | 18 (39%) |
| Obese Class 3 (>40) | 1 (2%) |
| Delta BMI
(change in BMI per month) | n= 43 |
| Median (SD) | −0.05 (0.2) |
| Range | −0.41 to+0.63 per month |
| Delta FVC
(Change in FVC per month) | n= 44 |
| Median (SD) | −0.3% (0.81%) |
| Range | −2.44% to+1.5% |